HeimBRM • ETR
add
Bristol-Myers Squibb Co
Við síðustu lokun
48,36 €
Dagbil
48,07 € - 48,92 €
Árabil
36,42 € - 54,30 €
Markaðsvirði
106,95 ma. USD
Meðalmagn
2,36 þ.
V/H-hlutf.
-
A/V-hlutfall
-
Aðalkauphöll
NYSE
Í fréttum
Investopedia
fyrir 3 vikum
Bristol Myers Squibb Stock Rises After Schizophrenia Drug Gets FDA Approval
1,27%
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
| (USD) | jún. 2024info | Breyting á/á |
|---|---|---|
Tekjur | 12,20 ma. | 8,69% |
Rekstrarkostnaður | 6,63 ma. | 3,25% |
Nettótekjur | 1,68 ma. | -18,96% |
Hagnaðarhlutfall | 13,77 | -25,45% |
Hagnaður á hvern hlut | 2,07 | 18,29% |
EBITDA | 5,22 ma. | 17,59% |
Virkt skatthlutfall | -30,95% | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
| (USD) | jún. 2024info | Breyting á/á |
|---|---|---|
Reiðufé og skammtímafjárfestingar | 6,65 ma. | -23,79% |
Heildareignir | 94,65 ma. | 1,24% |
Heildarskuldir | 77,58 ma. | 26,23% |
Eigið fé alls | 17,07 ma. | — |
Útistandandi hlutabréf | 2,03 ma. | — |
Eiginfjárgengi | 5,76 | — |
Arðsemi eigna | 6,71% | — |
Ávöxtun eigin fjár | 8,95% | — |
Peningaflæði
Breyting á handbæru fé
| (USD) | jún. 2024info | Breyting á/á |
|---|---|---|
Nettótekjur | 1,68 ma. | -18,96% |
Handbært fé frá rekstri | 2,33 ma. | 23,26% |
Reiðufé frá fjárfestingum | -1,32 ma. | -300,91% |
Reiðufé frá fjármögnun | -4,02 ma. | -85,14% |
Breyting á handbæru fé | -3,04 ma. | -387,64% |
Frjálst peningaflæði | 2,61 ma. | -2,24% |
Um
The Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company. Headquartered in Princeton, New Jersey, BMS is one of the world's largest pharmaceutical companies and consistently ranks on the Fortune 500 list of the largest U.S. corporations. For fiscal 2022, it had a total revenue of $46.2 billion.
Bristol Myers Squibb manufactures prescription pharmaceuticals and biologics in several therapeutic areas, including cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis, and psychiatric disorders.
BMS's primary research and development sites are located in Lawrence, New Jersey, Summit, New Jersey, formerly HQ of Celgene, New Brunswick, New Jersey, Redwood City, California, and Seville in Spain, with other sites in Devens and Cambridge, Massachusetts, Braine-l'Alleud, Belgium, Tokyo, Japan, Hyderabad; Bangalore India and Wirral, United Kingdom. BMS previously had an R&D site in Wallingford, Connecticut. Wikipedia
Framkvæmdastjóri
Stofnsett
1887
Höfuðstöðvar
Vefsvæði
Starfsfólk
34.100
